

# Daniel C Brennan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4702619/publications.pdf>

Version: 2024-02-01

262  
papers

16,886  
citations

20817

60  
h-index

17105

122  
g-index

266  
all docs

266  
docs citations

266  
times ranked

12693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis E virus infection and rejection in kidney transplant recipients. <i>Transplant Immunology</i> , 2022, 70, 101517.	1.2	5
2	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. <i>Clinical Transplantation</i> , 2022, 36, e14660.	1.6	2
3	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	1.6	14
4	COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. <i>Transplantation</i> , 2022, 106, e346-e347.	1.0	41
5	Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9507-9507.	1.6	7
6	Development and Validation of an Inflammatory-Frailty Index for Kidney Transplantation. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 470-477.	3.6	14
7	Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. <i>American Journal of Transplantation</i> , 2021, 21, 2498-2508.	4.7	63
8	Long-term kidney transplant graft survivalâ€™Making progress when most needed. <i>American Journal of Transplantation</i> , 2021, 21, 2824-2832.	4.7	86
9	Securing the future of kidney transplantation by addressing the challenges of transplant nephrology. <i>American Journal of Transplantation</i> , 2021, 21, 37-43.	4.7	6
10	Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration. <i>Transplantation Direct</i> , 2021, 7, e656.	1.6	8
11	Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation. <i>BMC Nephrology</i> , 2021, 22, 26.	1.8	6
12	Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts. <i>Kidney360</i> , 2021, 2, 729-736.	2.1	16
13	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2021, 105, 2632-2638.	1.0	4
14	Combining Clinical and Genetic Factors to Predict Tacrolimus Levels in Pediatric Solid Organ Transplants. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	0
15	Deceased-Donor Acute Kidney Injury and BK Polyomavirus in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 765-775.	4.5	4
16	Therapies for Chronic Allograft Rejection. <i>Frontiers in Pharmacology</i> , 2021, 12, 651222.	3.5	14
17	Chronic Active Antibody-Mediated Rejection Following COVID-19 Infection in a Kidney Transplant Recipient: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 1202-1206.	0.6	16
18	Donor-derived Cell-free DNA Kinetics Post-kidney Transplant Biopsy. <i>Transplantation Direct</i> , 2021, 7, e703.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Donor-Derived Cell-Free DNA in Kidney Transplantation: Origins, Present and a Look to the Future. <i>Medicina (Lithuania)</i> , 2021, 57, 482.	2.0	3
20	Association between ddâ€cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort. <i>Clinical Transplantation</i> , 2021, 35, e14402.	1.6	5
21	Longâ€term kidney function and survival in recipients of allografts from living kidney donors with hypertension: a national cohort study. <i>Transplant International</i> , 2021, 34, 1530-1541.	1.6	5
22	Cognitive impairment burden in older and younger adults across the kidney transplant care continuum. <i>Clinical Transplantation</i> , 2021, 35, e14425.	1.6	7
23	Changes in Functional Status Among Kidney Transplant Recipients: Data From the Scientific Registry of Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2104-2111.	1.0	6
24	Utility of Donor-Derived Cell-Free DNA in Detecting ABMR in Patients With AT1R Antibodies. <i>Kidney International Reports</i> , 2021, 6, 2706-2708.	0.8	3
25	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. <i>Kidney360</i> , 2021, 2, 1998-2009.	2.1	12
26	Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. <i>Transplantation</i> , 2021, 105, 170-176.	1.0	37
27	The Science Is Only as Good as the Data: The Case of Fontan-associated Liver Disease. <i>Transplantation</i> , 2021, 105, 23-24.	1.0	0
28	Three-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation in type 2 diabetes patients. <i>American Journal of Transplantation</i> , 2020, 20, 788-796.	4.7	28
29	Functional independence, access to kidney transplantation and waitlist mortality. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 870-877.	0.7	8
30	APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): DesignÂandÂRationale. <i>Kidney International Reports</i> , 2020, 5, 278-288.	0.8	62
31	Talimogene Laherparepvec Use in Kidney Transplant Recipient. <i>Transplantation</i> , 2020, 104, e109-e110.	1.0	2
32	Physical Impairment and Access to Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 367-373.	1.0	12
33	Kidney Dyads: Caregiver Burden and Relationship Strain Among Partners of Dialysis and Transplant Patients. <i>Transplantation Direct</i> , 2020, 6, e566.	1.6	5
34	Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 679-685.	2.0	6
35	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. <i>Clinical Transplantation</i> , 2020, 34, e14118.	1.6	4
36	Financial incentives versus standard of care to improve patient compliance with live kidney donor follow-up: protocol for a multi-center, parallel-group randomized controlled trial. <i>BMC Nephrology</i> , 2020, 21, 465.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Telemedicine in the Care of Kidney Transplant Recipients With Coronavirus Disease 2019: Case Reports. <i>Transplantation Proceedings</i> , 2020, 52, 2620-2625.	0.6	32
38	The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. <i>BMC Nephrology</i> , 2020, 21, 449.	1.8	61
39	General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection. <i>Current Transplantation Reports</i> , 2020, 7, 366-378.	2.0	8
40	Apical Sparing Pattern of Longitudinal Strain and Positive Bone Scintigraphy in Metastatic Myocardial Calcification. <i>JACC: Case Reports</i> , 2020, 2, 809-813.	0.6	2
41	Long-term renal function in living kidney donors with simple renal cysts: A retrospective cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13905.	1.6	3
42	Early Steroid Withdrawal in Deceased-Donor Kidney Transplant Recipients with Delayed Graft Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 175-185.	6.1	20
43	Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. <i>American Journal of Transplantation</i> , 2020, 20, 2997-3007.	4.7	50
44	Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	4.7	20
45	Economic impacts of alternative kidney transplant immunosuppression: A national cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13813.	1.6	2
46	Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. <i>Transfusion</i> , 2020, 60, 628-636.	1.6	14
47	Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2020, 6, e543.	1.6	36
48	Abundance of Multidrug Resistance Efflux Pumps in the Urinary Metagenome of Kidney Transplant Patients. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	2
49	Cognitive Function, Access to Kidney Transplantation, and Waitlist Mortality Among Kidney Transplant Candidates With or Without Diabetes. <i>American Journal of Kidney Diseases</i> , 2020, 76, 72-81.	1.9	20
50	The Impact of COVID-19 on the State of Clinical and Laboratory Research Globally in Transplantation in May 2020. <i>Transplantation</i> , 2020, 104, 2252-2257.	1.0	4
51	COVID-19 Early After a Deceased Donor Kidney Transplant Surgery. <i>Transplantation</i> , 2020, 104, e354-e355.	1.0	4
52	Donor-derived Cell-free DNA and the Prediction of BK Virus-associated Nephropathy. <i>Transplantation Direct</i> , 2020, 6, e622.	1.6	25
53	Moving from transplant as a treatment to transplant as a cure. <i>Journal of Clinical Investigation</i> , 2020, 130, 2189-2191.	8.2	1
54	ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 202-209.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor-recipient combination. <i>American Journal of Transplantation</i> , 2019, 19, 425-433.	4.7	66
56	Risk of ESKD in Older Live Kidney Donors with Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1048-1055.	4.5	29
57	Total Penis, Scrotum, and Lower Abdominal Wall Transplantation. <i>New England Journal of Medicine</i> , 2019, 381, 1876-1878.	27.0	31
58	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. <i>Transplant International</i> , 2019, 32, 1268-1276.	1.6	44
59	Frailty and Access to Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 576-582.	4.5	89
60	Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 2252-2261.	4.7	24
61	The changing landscape of live kidney donation in the United States from 2005 to 2017. <i>American Journal of Transplantation</i> , 2019, 19, 2614-2621.	4.7	42
62	WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure. <i>American Journal of Transplantation</i> , 2019, 19, 2833-2845.	4.7	7
63	Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. <i>Transplantation</i> , 2019, 103, 2373-2382.	1.0	36
64	Everyday People Sing a Simple Song: Establishing a Core Outcome for Life Participation. <i>Transplantation</i> , 2019, 103, 1078-1079.	1.0	0
65	The landscape of international living kidney donation in the United States. <i>American Journal of Transplantation</i> , 2019, 19, 2009-2019.	4.7	18
66	The national landscape of deceased donor kidney transplantation for the highly sensitized: Transplant rates, waitlist mortality, and posttransplant survival under KAS. <i>American Journal of Transplantation</i> , 2019, 19, 1129-1138.	4.7	61
67	Cytomegalovirus. <i>Transplantation</i> , 2018, 102, 898-899.	1.0	2
68	Incidence, Risk Factors, and Sequelae of Post-kidney Transplant Delirium. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1752-1759.	6.1	86
69	Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. <i>Transplant International</i> , 2018, 31, 198-211.	1.6	46
70	Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2018, 71, 315-326.	1.9	62
71	Antidepressant medication use before and after kidney transplant: implications for outcomes - a retrospective study. <i>Transplant International</i> , 2018, 31, 20-31.	1.6	12
72	Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. <i>Transplantation Direct</i> , 2018, 4, e389.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Influence of pretransplant midodrine use on outcomes after kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13366.	1.6	7
74	Transformation in Immunosuppression: Are We Ready for it?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1791-1792.	6.1	2
75	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	6.1	365
76	Complete Genome Sequence of BK Polyomavirus Subtype Ib-1 Detected in a Kidney Transplant Patient with BK Viremia Using Shotgun Sequencing. <i>Genome Announcements</i> , 2017, 5, .	0.8	4
77	Biologics in Transplantation (Anti-thymocyte Globulin, Belatacept, Alemtuzumab): How Should We Use Them?. <i>Current Transplantation Reports</i> , 2017, 4, 82-90.	2.0	0
78	Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor. <i>Transplantation</i> , 2017, 101, e287-e288.	1.0	3
79	Diabetes Mellitus in Living Pancreas Donors. <i>Transplantation</i> , 2017, 101, 1276-1281.	1.0	8
80	Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice. <i>Transplantation</i> , 2017, 101, 858-866.	1.0	21
81	Epstein-Barr virus and renal transplantation. <i>Transplantation Reviews</i> , 2017, 31, 55-60.	2.9	39
82	Letermovir for the management of cytomegalovirus infection. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 235-241.	4.1	39
83	Transplant Center Volume and the Risk of Pancreas Allograft Failure. <i>Transplantation</i> , 2017, 101, 2757-2764.	1.0	43
84	A Snapshot of Antibody-Mediated Rejection Goes Viral. <i>Transplantation</i> , 2017, 101, 227.	1.0	0
85	Singing a New SONG. <i>Transplantation</i> , 2017, 101, 1748-1750.	1.0	1
86	The Privilege of Induction Avoidance and Calcineurin Inhibitors Withdrawal in 2 Haplotype HLA Matched White Kidney Transplantation. <i>Transplantation Direct</i> , 2017, 3, e133.	1.6	3
87	Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay. <i>Transplantation Direct</i> , 2017, 3, e194.	1.6	7
88	Effects of recurrent urinary tract infections on graft and patient outcomes after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1758-1766.	0.7	50
89	Selected Mildly Obese Donors Can Be Used Safely in Simultaneous Pancreas and Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1159-1166.	1.0	16
90	Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1314-1325.	6.1	32

#	ARTICLE	IF	CITATIONS
91	Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation. <i>Transplant International</i> , 2017, 30, 153-161.	1.6	20
92	Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. <i>Translational Research</i> , 2017, 181, 59-70.	5.0	51
93	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. <i>Journal of Applied Laboratory Medicine</i> , The, 2017, 2, 309-321.	1.3	59
94	Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. <i>American Journal of Transplantation</i> , 2016, 16, 509-517.	4.7	134
95	Clinical and economic consequences of first-year urinary tract infections, sepsis, and pneumonia in contemporary kidney transplantation practice. <i>Transplant International</i> , 2016, 29, 241-252.	1.6	54
96	Pretransplant Midodrine Use. <i>Transplantation</i> , 2016, 100, 1086-1093.	1.0	25
97	Immunosuppressive Agents. , 2016, , 31-46.		3
98	Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. <i>Transplant International</i> , 2016, 29, 1226-1236.	1.6	50
99	Extended-release tacrolimus tablets for preventing organ transplant rejection. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1079-1086.	0.8	0
100	Introduction: Kidney Transplantation and Viral Infection. <i>Seminars in Nephrology</i> , 2016, 36, 343.	1.6	5
101	Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. <i>Clinical Transplantation</i> , 2016, 30, 435-444.	1.6	7
102	A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms. <i>Scientific Reports</i> , 2016, 6, 33327.	3.3	44
103	Switching <sc>ST</sc>udy of Kidney TRAnsplant <sc>PA</sc>tients with Tremor to <sc>LCP</sc>â€TacrO (<sc>STRATO</sc>): an openâ€label, multicenter, prospective phase 3b study. <i>Clinical Transplantation</i> , 2015, 29, 796-805.	1.6	86
104	Tacrolimusâ€Induced Cardiomyopathy in an Adult Renal Transplant Recipient. <i>Pharmacotherapy</i> , 2015, 35, 1109-1116.	2.6	10
105	Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. <i>Trials</i> , 2015, 16, 365.	1.6	30
106	Quantifying Prognostic Impact of Prescription Opioid Use Before Kidney Transplantation Through Linked Registry and Pharmaceutical Claims Data. <i>Transplantation</i> , 2015, 99, 187-196.	1.0	41
107	Gender differences in use of prescription narcotic medications among living kidney donors. <i>Clinical Transplantation</i> , 2015, 29, 927-937.	1.6	10
108	Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. <i>Transplant International</i> , 2015, 28, 1121-1125.	1.6	34

#	ARTICLE	IF	CITATIONS
109	Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1658-1666.	1.0	33
110	Race, Relationship and Renal Diagnoses After Living Kidney Donation. <i>Transplantation</i> , 2015, 99, 1723-1729.	1.0	48
111	A Case Report of Adrenocorticotrophic Hormone to Treat Recurrent Focal Segmental Glomerular Sclerosis Post-Transplantation and Biomarker Monitoring. <i>Frontiers in Medicine</i> , 2015, 2, 13.	2.6	9
112	Single-Dose Rituximab for Recurrent Glomerulonephritis Post-Renal Transplant. <i>American Journal of Nephrology</i> , 2015, 41, 37-47.	3.1	13
113	Gout after Living Kidney Donation: Correlations with Demographic Traits and Renal Complications. <i>American Journal of Nephrology</i> , 2015, 41, 231-240.	3.1	27
114	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	6.1	172
115	Associations of Pre-Transplant Prescription Narcotic Use with Clinical Complications after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2015, 41, 165-176.	3.1	54
116	Pulmonary Phaeohyphomycosis Caused by Phaeoacremonium in a Kidney Transplant Recipient: Successful Treatment with Posaconazole. <i>Case Reports in Medicine</i> , 2014, 2014, 1-5.	0.7	13
117	The relevance of the FAVORIT blood pressure associations. <i>Nature Reviews Nephrology</i> , 2014, 10, 366-367.	9.6	0
118	Cytomegalovirus and Anemia: Not Just for Transplant Anymore. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1613-1615.	6.1	3
119	Understanding Antihypertensive Medication Use after Living Kidney Donation through Linked National Registry and Pharmacy Claims Data. <i>American Journal of Nephrology</i> , 2014, 40, 174-183.	3.1	26
120	JC polyoma virus and kidney disease. <i>Kidney International</i> , 2014, 85, 1242.	5.2	9
121	Graft-Versus-Host Disease After Simultaneous Pancreas-Kidney Transplantation: A Case Report and Review of the Literature. <i>American Journal of Transplantation</i> , 2014, 14, 2651-2656.	4.7	18
122	Delayed-Onset Cytomegalovirus Disease Coded During Hospital Readmission After Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 187-194.	1.0	36
123	Treatment of BK Viremia after Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 445-447.	4.5	7
124	Early Clinical Complications After ABO-Incompatible Live-Donor Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 54-65.	1.0	77
125	Symptomatic hyperammonemia after lung transplantation: Lessons learnt. <i>Hemodialysis International</i> , 2014, 18, 185-191.	0.9	29
126	The role of rabbit antithymocyte globulin in renal transplantation. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 971-987.	0.8	1



#	ARTICLE	IF	CITATIONS
127	Consistency of Racial Variation in Medical Outcomes Among Publicly and Privately Insured Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 316-324.	1.0	38
128	Understanding Medical Care of Transplant Recipients through Integrated Registry and Pharmacy Claims Data. <i>American Journal of Nephrology</i> , 2013, 38, 420-429.	3.1	10
129	American Society of Nephrology Quiz and Questionnaire 2012: <i>Transplantation</i> . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1267-1272.	4.5	1
130	Starting Well: Induction Immunosuppression after Organ Transplantation. <i>Transplant International</i> , 2013, 26, 661-661.	1.6	0
131	Selection of induction therapy in kidney transplantation. <i>Transplant International</i> , 2013, 26, 662-672.	1.6	72
132	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. <i>Reviews in Medical Virology</i> , 2013, 23, 97-125.	8.3	60
133	Novel immunosuppressive agents in kidney transplantation. <i>World Journal of Transplantation</i> , 2013, 3, 68.	1.6	47
134	Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients. <i>PLoS Pathogens</i> , 2012, 8, e1002650.	4.7	83
135	Randomized Trial of Pre-Emptive or Prophylactic Valganciclovir Therapy for Prevention of Cytomegalovirus Infection in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1446-1448.	6.1	0
136	Obesity and Kidney Transplant Candidates: How Big Is Too Big for Transplantation?. <i>American Journal of Nephrology</i> , 2012, 36, 575-586.	3.1	124
137	Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients. <i>Transplantation</i> , 2012, 94, 331-337.	1.0	32
138	Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2012, 93, 1075-1085.	1.0	129
139	Induction Therapy in Renal Transplant Recipients. <i>Drugs</i> , 2012, 72, 671-683.	10.9	31
140	De Novo Membranoproliferative Glomerulonephritis III in a renal transplant patient: Case report and review of the literature. <i>Transplant International</i> , 2012, 25, e58-e61.	1.6	2
141	The Long-Term Outcomes and Costs of Diabetes Mellitus among Renal Transplant Recipients: Tacrolimus versus Cyclosporine. <i>Value in Health</i> , 2011, 14, 443-449.	0.3	9
142	Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. <i>Archives of Medical Science</i> , 2011, 2, 278-286.	0.9	34
143	Cardioprotective Medication Use After Acute Myocardial Infarction in Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 91, 1120-1126.	1.0	14
144	Associations of Recipient Illness History With Hypertension and Diabetes After Living Kidney Donation. <i>Transplantation</i> , 2011, 91, 1227-1232.	1.0	6

#	ARTICLE	IF	CITATIONS
145	Impaired renal function is associated with worse self-reported outcomes after kidney transplantation. <i>Quality of Life Research</i> , 2011, 20, 1689-1698.	3.1	23
146	Inhibitory Interactions between BK and JC Virus among Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 825-831.	6.1	48
147	Three-year post-transplant Medicare payments in kidney transplant recipients: associations with pre-transplant comorbidities. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2011, 22, 24-39.	0.3	4
148	Impact of Prophylactic Versus Preemptive Valganciclovir on Long-Term Renal Allograft Outcomes. <i>Transplantation</i> , 2010, 90, 412-418.	1.0	47
149	Serum Sickness After Treatment With Rabbit Antithymocyte Globulin in Kidney Transplant Recipients With Previous Rabbit Exposure. <i>American Journal of Kidney Diseases</i> , 2010, 55, 141-143.	1.9	33
150	The Tradeoff Between the Risks of Acute Rejection and New-Onset Diabetes After Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1026-1028.	1.9	10
151	Racial Variation in Medical Outcomes among Living Kidney Donors. <i>New England Journal of Medicine</i> , 2010, 363, 724-732.	27.0	261
152	Human polyoma viruses and disease with emphasis on clinical BK and JC. <i>Journal of Clinical Virology</i> , 2010, 47, 306-312.	3.1	118
153	Current Concepts of Immunosuppression and Side Effects. , 2009, , 11-30.		0
154	Sensitivity of Billing Claims for Cardiovascular Disease Events among Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1213-1221.	4.5	40
155	Incremental Value of the Pancreas Allograft to the Survival of Simultaneous Pancreas-Kidney Transplant Recipients. <i>Diabetes Care</i> , 2009, 32, 600-602.	8.6	38
156	Iron deficiency anemia and iron losses after renal transplantation. <i>Transplant International</i> , 2009, 22, 434-440.	1.6	33
157	<i>Mille Verba</i>: Seeking Safe and Efficacious Anemia Management. <i>Seminars in Dialysis</i> , 2009, 22, 590-591.	1.3	5
158	The impact of kidney transplantation on heart failure risk varies with candidate body mass index. <i>American Heart Journal</i> , 2009, 158, 972-982.	2.7	33
159	Bariatric Surgery Among Kidney Transplant Candidates and Recipients: Analysis of the United States Renal Data System and Literature Review. <i>Transplantation</i> , 2009, 87, 1167-1173.	1.0	139
160	Increasing Incidence of New-Onset Diabetes After Transplant Among Pediatric Renal Transplant Patients. <i>Transplantation</i> , 2009, 88, 367-373.	1.0	26
161	Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. <i>Transplantation</i> , 2009, 87, 233-242.	1.0	524
162	Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation: Application of Statistical Approaches to Reduce Bias in Observational Comparisons. <i>Transplantation</i> , 2009, 87, 1520-1529.	1.0	51

#	ARTICLE	IF	CITATIONS
163	Rabbit Antithymocyte Globulin Is More Beneficial in Standard Kidney Than In Extended Donor Recipients. <i>Transplantation</i> , 2009, 87, 1372-1376.	1.0	17
164	Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 41-52.	1.6	50
165	BK virus antibody titers and intensity of infections after renal transplantation. <i>Journal of Clinical Virology</i> , 2008, 43, 184-189.	3.1	93
166	The role of tacrolimus in renal transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 635-643.	1.8	82
167	Variations in the Risk for Cerebrovascular Events after Kidney Transplant Compared with Experience on the Waiting List and after Graft Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1090-1101.	4.5	75
168	Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction. <i>New England Journal of Medicine</i> , 2008, 359, 1736-1738.	27.0	112
169	Cardiac Evaluation before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1115-1124.	4.5	44
170	Novel Methods for Tracking Long-Term Maintenance Immunosuppression Regimens. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 117-124.	4.5	11
171	Expanding the Evidence Base in Transplantation: The Complementary Roles of Randomized Controlled Trials and Outcomes Research. <i>Transplantation</i> , 2008, 86, 18-25.	1.0	14
172	A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10-Year Results. <i>Transplantation</i> , 2008, 86, 947-952.	1.0	71
173	Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 602-603.	2.0	10
174	Identification of a Novel Polyomavirus from Patients with Acute Respiratory Tract Infections. <i>PLoS Pathogens</i> , 2007, 3, e64.	4.7	581
175	Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 517-523.	4.5	31
176	Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1027-1034.	1.0	122
177	Utility of a Mathematical Nomogram to Predict Delayed Graft Function: A Single-Center Experience???Critique. <i>Transplantation</i> , 2007, 83, 524-525.	1.0	3
178	Prevention and management of cytomegalovirus infection in solid-organ transplantation. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 295-304.	4.4	27
179	International Trial of the Edmonton Protocol for Islet Transplantation. <i>New England Journal of Medicine</i> , 2006, 355, 1318-1330.	27.0	1,754
180	Long-Term Trends in Allograft Survival. <i>Advances in Chronic Kidney Disease</i> , 2006, 13, 11-17.	1.4	22

#	ARTICLE	IF	CITATIONS
181	Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation. <i>New England Journal of Medicine</i> , 2006, 355, 1967-1977.	27.0	675
182	Thymoglobulin Induction Is Safe and Effective in Live-Donor Renal Transplantation: A Single Center Experience. <i>Transplantation</i> , 2006, 81, 1285-1289.	1.0	53
183	EBV-associated recurrent Hodgkin's disease after renal transplantation. <i>Transplant International</i> , 2006, 19, 338-341.	1.6	13
184	Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2006, 6, 2134-2143.	4.7	294
185	Is there a correlation between atherosclerosis and renal resistive indices in kidney transplant recipients?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 64-65.	2.0	1
186	Incidence, Predictors, and Associated Outcomes of Atrial Fibrillation after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 288-296.	4.5	63
187	Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2299-2306.	6.1	25
188	Living donation decision making: recipients' concerns and educational needs. <i>Progress in Transplantation</i> , 2006, 16, 17-23.	0.7	86
189	Renal Graft Survival and Calcineurin Inhibitor. <i>Transplantation</i> , 2005, 80, 629-633.	1.0	23
190	Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. <i>Transplantation</i> , 2005, 79, 1277-1286.	1.0	842
191	A Randomized, Prospective, Pharmacoeconomic Trial of Tacrolimus versus Cyclosporine in Combination with Thymoglobulin in Renal Transplant Recipients. <i>Transplantation</i> , 2005, 80, 41-46.	1.0	60
192	Tularemia in a Kidney Transplant Recipient: An Unsuspected Case and Literature Review. <i>American Journal of Kidney Diseases</i> , 2005, 45, 926-929.	1.9	23
193	De Novo Congestive Heart Failure After Kidney Transplantation: A Common Condition With Poor Prognostic Implications. <i>American Journal of Kidney Diseases</i> , 2005, 46, 720-733.	1.9	110
194	Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report. <i>American Journal of Transplantation</i> , 2005, 5, 218-227.	4.7	268
195	Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction. <i>American Journal of Transplantation</i> , 2005, 5, 582-594.	4.7	613
196	Consequences of Eliminating HLA-B in Deceased Donor Kidney Allocation to Increase Minority Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1090-1098.	4.7	23
197	Donor Origin of BK Virus in Renal Transplantation and Role of HLA C7 in Susceptibility to Sustained BK Viremia. <i>American Journal of Transplantation</i> , 2005, 5, 2213-2221.	4.7	251
198	The Life-Years Saved by a Deceased Organ Donor. <i>American Journal of Transplantation</i> , 2005, 5, 2289-2296.	4.7	118

#	ARTICLE	IF	CITATIONS
199	Incidence and Predictors of Myocardial Infarction after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 496-506.	6.1	307
200	Infectious complications in kidney transplant recipients: review of the literature. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2005, 16, 453-97.	0.3	9
201	Statin use after renal transplantation: a systematic quality review of trial-based evidence. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2378-2386.	0.7	42
202	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	1.6	139
203	Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Twice Daily Versus Once Daily Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 621-625.	4.7	47
204	Cost-Effectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney Transplant. <i>American Journal of Transplantation</i> , 2004, 4, 1703-1708.	4.7	90
205	Cyclosporine Minimization and Cost Reduction in Renal Transplant Recipients Receiving a C2-Monitored, Cyclosporine-Based Quadruple Immunosuppressive Regimen. <i>Transplantation</i> , 2004, 78, 1198-1203.	1.0	14
206	Five-Year Follow Up of Thymoglobulin Versus ATGAM Induction in Adult Renal Transplantation. <i>Transplantation</i> , 2004, 78, 136-141.	1.0	118
207	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	1.6	42
208	The Association of Cytomegalovirus Sero-Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis. <i>American Journal of Transplantation</i> , 2003, 3, 445-451.	4.7	66
209	Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 590-598.	4.7	354
210	West Nile Virus-Associated Meningoencephalitis in Two Chronically Immunosuppressed Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1312-1315.	4.7	30
211	Nomogram for Predicting the Likelihood of Delayed Graft Function in Adult Cadaveric Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2967-2974.	6.1	199
212	Cytomegalovirus Disease after Prophylaxis with Oral Ganciclovir in Renal Transplantation: The Importance of HLA-DR Matching. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 780-785.	6.1	58
213	Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1197-1200.	0.7	14
214	CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 397-402.	0.7	47
215	Leflunomide: is there a place for its use in transplantation?. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 317-322.	1.6	4
216	Functional Antibodies to Leukocyte Adhesion Molecules in Antithymocyte Globulins.. <i>Transplantation</i> , 2003, 75, 577-578.	1.0	12

#	ARTICLE	IF	CITATIONS
217	The expanded criterial donor dilemma in cadaveric renal transplantation. <i>Transplantation</i> , 2003, 75, 1940-1945.	1.0	107
218	Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. <i>Transplantation</i> , 2003, 76, 1686-1690.	1.0	26
219	Sirolimus-induced leukocytoclastic vasculitis. <i>Transplantation</i> , 2002, 74, 739-740.	1.0	47
220	Prospective, Pilot, Open-Label, Short-Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2002, 2, 867-871.	4.7	54
221	IN VITRO T CELL PROLIFERATION FROM KIDNEY ALLOGRAFT BIOPSIES WITH UNREMARKABLE PATHOLOGY. <i>Transplantation</i> , 2002, 73, 142-145.	1.0	6
222	SHORT COURSE INDUCTION IMMUNOSUPPRESSION WITH THYMOGLOBULIN FOR RENAL TRANSPLANT RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 2002, 73, 473-475.	1.0	113
223	Effect of Extended Coverage of Immunosuppressive Medications by Medicare on the Survival of Cadaveric Renal Transplants. <i>American Journal of Transplantation</i> , 2001, 1, 69-73.	4.7	60
224	The Economic Impact of Preservation Time in Cadaveric Liver Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 360-365.	4.7	18
225	Cytomegalovirus in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 848-855.	6.1	209
226	Infectious Complications in Renal Transplant Recipients. <i>Advances in Chronic Kidney Disease</i> , 2000, 7, 131-146.	2.1	20
227	ECONOMIC OUTCOMES OF SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION (SKP) COMPARED TO KIDNEY ALONE (KA).. <i>Transplantation</i> , 2000, 69, S270.	1.0	0
228	ECONOMIC COST OF EXPANDED CRITERIA DONORS IN CADAVERIC RENAL TRANSPLANTATION: ANALYSIS OF MEDICARE PAYMENTS <sup>1</sup> . <i>Transplantation</i> , 2000, 70, 755-760.	1.0	75
229	ECONOMIC IMPACT OF COLD ISCHEMIA IN LIVER TRANSPLANT.. <i>Transplantation</i> , 2000, 69, S367.	1.0	0
230	A 3-Year Follow-Up of Pre-Emptive vs Deferred Treatment of Cytomegalovirus Disease in Renal Transplantation. <i>Clinical Drug Investigation</i> , 2000, 19, 367-374.	2.2	8
231	CADAVERIC VERSUS LIVING DONOR KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 311.	1.0	71
232	THE ECONOMIC BENEFIT OF ALLOCATION OF KIDNEYS BASED ON CROSS-REACTIVE GROUP MATCHING <sup>12</sup> . <i>Transplantation</i> , 2000, 70, 537-540.	1.0	3
233	The Economic Implications of HLA Matching in Cadaveric Renal Transplantation. <i>New England Journal of Medicine</i> , 1999, 341, 1440-1446.	27.0	60
234	Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. <i>Kidney International</i> , 1999, 56, 685-691.	5.2	6

#	ARTICLE	IF	CITATIONS
235	A RANDOMIZED, DOUBLE-BLINDED COMPARISON OF THYMOGLOBULIN VERSUS ATGAM FOR INDUCTION IMMUNOSUPPRESSIVE THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS <sup>1,2</sup> . <i>Transplantation</i> , 1999, 67, 1011-1018.	1.0	341
236	RECURRENT AND DE NOVO GLOMERULAR DISEASE AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 1999, 68, 635-641.	1.0	213
237	A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information. <i>Pharmacoeconomics</i> , 1998, 14, 71-77.	3.3	0
238	The Effect of Tolerance to Noninherited Maternal HLA Antigens on the Survival of Renal Transplants from Sibling Donors. <i>New England Journal of Medicine</i> , 1998, 339, 1657-1664.	27.0	267
239	Quantitative Polymerase Chain Reaction to Predict Occurrence of Symptomatic Cytomegalovirus Infection and Assess Response to Ganciclovir Therapy in Renal Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1998, 178, 626-635.	4.0	101
240	TRANSPLANTATION OF VASCULARIZED ALLOGENEIC SKELETAL MUSCLE FOR SCALP RECONSTRUCTION IN A RENAL TRANSPLANT PATIENT. <i>Transplantation</i> , 1998, 65, 1605-1610.	1.0	16
241	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION <sup>1,2</sup> . <i>Transplantation</i> , 1998, 66, 29-37.	1.0	273
242	A Pharmacoeconomic Comparison of Antithymocyte Globulin and Muromonab CD3 Induction Therapy in Renal Transplant Recipients. <i>Pharmacoeconomics</i> , 1997, 11, 237-245.	3.3	12
243	Cytomegalovirus and HLA-A, B, and DR locus interactions: Impact on renal transplant graft survival. <i>American Journal of Kidney Diseases</i> , 1997, 30, 766-771.	1.9	15
244	The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. <i>American Journal of Kidney Diseases</i> , 1997, 29, 428-434.	1.9	52
245	Renal Allograft Infiltrating Lymphocytes: Frequency of Tissue Specific Lymphocytes. <i>Human Immunology</i> , 1997, 55, 140-147.	2.4	6
246	PERIPHERAL BLOOD MICROCHIMERISM IN HUMAN LIVER AND RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 64, 427-432.	1.0	81
247	PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS <sup>1,2,???</sup> . <i>Transplantation</i> , 1997, 64, 1843-1846.	1.0	141
248	INCREASED EXPRESSION OF THE HDJ-2 HEAT SHOCK PROTEIN IN BIOPSIES OF HUMAN REJECTED KIDNEY <sup>1</sup> . <i>Transplantation</i> , 1996, 61, 963-967.	1.0	20
249	LIVING UNRELATED RENAL TRANSPLANTATION FOR SICKLE CELL NEPHROPATHY. <i>Transplantation</i> , 1995, 59, 794-795.	1.0	8
250	DONOR-SPECIFIC TRANSFUSIONS HAVE LONG-TERM BENEFICIAL EFFECTS FOR HUMAN RENAL ALLOGRAFTS <sup>1</sup> . <i>Transplantation</i> , 1995, 60, 1395-1401.	1.0	69
251	Common variable immunodeficiency in a renal transplant patient with severe recurrent bacterial infection: A case report and review of the literature. <i>American Journal of Kidney Diseases</i> , 1995, 25, 947-951.	1.9	18
252	Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: A review of efficacy and mechanisms. <i>American Journal of Kidney Diseases</i> , 1995, 26, 701-715.	1.9	68

#	ARTICLE	IF	CITATIONS
253	IMPROVED TECHNIQUE FOR TRANSDUODENAL PANCREAS TRANSPLANT BIOPSY. Transplantation, 1994, 57, 752.	1.0	25
254	Colony stimulating factor-1 in the induction of lupus nephritis. Kidney International, 1993, 43, 1000-1009.	5.2	75
255	Treatment of HUS/TTP. American Journal of Kidney Diseases, 1992, 19, 391-393.	1.9	3
256	Cultured mesangial cells from autoimmune MRL-lpr mice have decreased secreted and surface M-CSF. Kidney International, 1992, 42, 279-284.	5.2	13
257	Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney International, 1992, 42, 851-859.	5.2	60
258	Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF $\alpha$ . Kidney International, 1991, 40, 203-211.	5.2	141
259	Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. Kidney International, 1990, 38, 417-425.	5.2	114
260	Mesangial cell accessory functions: Mediation by intercellular adhesion molecule-1. Kidney International, 1990, 38, 1039-1046.	5.2	86
261	Partial lipodystrophy magnetic resonance findings in one case. The Journal of Computed Tomography, 1988, 12, 287-291.	0.1	5
262	Donor Derived Cell Free DNA in Kidney Transplantation: The Circa 2020â€“2021 Update. Transplant International, 0, 35, .	1.6	15